Pulished Date October, 2018
ID: 779
Share on
Share on

North America Liver Cancer Therapeutics Market By Type (Primary, Secondary And Benign Liver Growths), By Therapeutics (Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma And Targeted Therapy), By End-User (Pediatrics And Adults) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts 2018-2023

Pulished: October, 2018
ID: 779
Pages: 145

North America Liver Cancer Therapeutics Market was worth $224.68 million in 2018 and estimated to be growing at a CAGR of 8.56%, to reach $338.77 million by 2023 North America has the largest market share for lung cancer diagnostics and therapeutics market. This is due to technological innovations in cancer treatment devices.

With advancement in technology, novel drugs are being developed which work in a different way from usual chemotherapy drugs, by targeting precise parts of cancer cells or their neighbouring environment. Treating cancer is still not easy because disease symptoms generally appear in the late stage of the disease, resulting in a low diagnosis rate that in turn disturbs the patient volume available for treatment.

Technological developments, for instance non-invasive radiation therapy and rising incidence of cancer are key drivers for the North America lung cancer therapeutic market. Moreover, increasing government support and funding for research and development field has promoted the market growth. On the other hand, high costs associated with research activities and the expiry of copyrights of some bestseller drugs are obstructing the growth of the market.

The North America liver cancer therapeutics market is segmented on the basis of type into primary, secondary and benign liver growths. On the basis of therapeutics market is bifurcated into hepatocellular carcinoma, Cholangio carcinoma, Hepatoblastoma and targeted therapy. By end-users the market is divided amongst pediatrics and adults. Hepatocellular Carcinoma is the largest segment for therapeutics type due to the high prevalence of this type of liver cancer among people.

Based on geography the market is analysed under various regions namely, USA and Canada. US leads the North America region market due to high number of cancer cases in US which is augmenting the liver cancer therapeutics market for the country.

Some of the key contributors in the industry include Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Primary    

                             5.1.2 Secondary             

                             5.1.3 Benign Liver growths         

              5.2 By Therapeutics                     

                             5.2.1 Hepatocellular Carcinoma

                             5.2.2 Cholangio carcinoma        

                             5.2.3 Hepatoblastoma  

                             5.2.4 Targeted Therapy

              5.3 By End-Users                          

                             5.3.1 Pediatrics

                             5.3.2 Adults      

6. Geographical Analysis                                         

                             6.1 Introduction             

                             6.2 United States           

                             6.3 Canada       

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Alnylam Pharmaceuticals Inc.                          

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 ImClone Systems Inc.                          

              9.3 Onyx Pharmaceuticals Inc.                 

              9.4 F. Hoffmann-La Roche Ltd.                

              9.5 Pfizer Inc.                  

              9.6 ArQule Inc.               

              9.7 Jennerex Biotherapeutics Inc.                         

              9.8 Celsion Corp.                          

              9.9 Bayer Schering Pharma AG                

              9.10 4SC AG                    

              9.11 Bristol-Myers Squibb Company                    

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Liver Cancer Diagnostics and Therapeutics Market By Region, From 2018-2023 (USD Million)
  2. North America Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  3. North America Primary Market By Region, From 2018-2023 (USD Million)
  4. North America Secondary Market By Region, From 2018-2023 (USD Million)
  5. North America Benign Liver growths Market By Region, From 2018-2023 (USD Million)
  6. North America Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  7. North America Hepatocellular Carcinoma Market By Region, From 2018-2023 (USD Million)
  8. North America Cholangio carcinoma Market By Region, From 2018-2023 (USD Million)
  9. North America Hepatoblastoma Market By Region, From 2018-2023 (USD Million)
  10. North America Targeted Therapy Market By Region, From 2018-2023 (USD Million)
  11. North America Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)
  12. North America Pediatrics Market By Region, From 2018-2023 (USD Million)
  13. North America Adults Market By Region, From 2018-2023 (USD Million)
  14. United States Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  15. United States Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  16. United States Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)
  17. Canada Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  18. Canada Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  19. Canada Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients